Key result
Intravenous M201-A proves safe in healthy volunteers up to /kg without significant QTc prolongation.
Why the study?
Although catheter ablation can stop persistent AF, it does not address recurrence, prompting investigation into the RyR2 inhibitor M201-A for AF conversion and prevention.
Does the RyR2 inhibitor M201-A/K201 improve electrophysiological parameters and convert atrial fibrillation?
RCT (n=39)
Double-blind
Randomized
No
Does the RyR2 inhibitor M201-A/K201 improve electrophysiological parameters and convert atrial fibrillation?
M201-A, an active metabolite of K201, demonstrates favorable atrial-selective electrophysiological properties and shows early clinical potential for converting atrial fibrillation.
Answers are grounded in this paper and cite their sources.
M201-A may aid AF conversion and post-ablation recurrence prevention; leaves open efficacy in larger randomized trials.
Conversion and prevention of atrial fibrillation (AF) are essential requirements for its treatment. Abnormal leak of calcium from the sarcoplasmic reticulum via the ryanodine receptor 2 (RyR2) during diastole is considered a major cause of AF. Although catheter ablation (CA) has made it possible to stop persistent AF, it does not address recurrence. In this context, we describe the additional pharmacological and antiarrhythmic effects of the RyR2 inhibitor M201-A, including the results of a Phase I study. M201-A inhibited I KACh at an IC 50 value of 0.35 μM, which was associated with a 38% increase in the atrial effective refractory period (ERP) and high atrial selectivity with an atrial ERP/ventricular ERP of 5.7. M201-A inhibited I Kr (IC 50 value of 0.43 μM) but induced only a limited prolongation in the action potential duration in rabbit ventricular cells and human-induced pluripotent stem cell-derived cardiomyocyte cells. M201-A is an r-enantiomer of the active metabolite M201-R of K201. After orally administering 540 mg of K201 in patients with AF, the unbound drug concentration of M201-R was 30-fold higher (approximately 15-fold for M201-A) than that of K201, and AF was converted in 6 of the 12 patients (50%) during the first 2 h following administration. M201-A was the main contributor with a stronger bioactive metabolite than M201-B (s-enantiomer) and M201-R. Furthermore, M201-A is 5-fold more biologically active than K201 in humans due to protein binding rates, these pharmacological properties hold promise as a new therapeutic strategy for AF, particularly the prevention of recurrence after CA.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2025) conducted an RCT in Healthy volunteers (n=39). M201-A vs. Placebo was evaluated on Safety and tolerability. Intravenous administration of M201-A in healthy male volunteers was safe and well-tolerated up to /kg, with no serious adverse events or significant QTc prolongation.
Synapse has enriched 10 related papers. Consider them for comparative context: